Evidence map›Paper›PMID 40950950›Full record

ArticleThe Lancet regional health. Europe2025

Yeast fungaemia among injection drug users in France (2012-2022): a cross-sectional observational study.

Olivier Paccoud, Olivier Lortholary, Sebastien Imbert, Valerie Letscher-Bru, Karine Boukris-Sitbon, Thomas Obadia, Frederic Dalle, Lilia Hasseine, Florent Morio, Antoine Huguenin and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Olivier PaccoudUniversité Paris Cité, Department of Infectious Diseases and Tropical Medicine, Necker - Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, 75014, France.
Olivier LortholaryUniversité Paris Cité, Department of Infectious Diseases and Tropical Medicine, Necker - Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, 75014, France.
Sebastien ImbertService de Parasitologie - Mycologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, F-33075, France.
Valerie Letscher-BruMycology-Parasitology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Karine Boukris-SitbonInstitut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Mycology Translational Research Group, Mycology Department, Paris, France.
Thomas ObadiaInstitut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Mycology Translational Research Group, Mycology Department, Paris, France.
Frederic DalleMycology-Parasitology Department, Centre Hospitalier Universitaire (CHU) Dijon, Dijon, France.
Lilia HasseineParasitologie - Mycologie, Hopital de l'Archet, CHU Nice, Nice, France.
Florent MorioNantes Université, CHU Nantes, Cibles et Médicaments des Infections et de l'Immunité, Nantes, UR1155, France.
Antoine HugueninUniversité de Reims Champagne Ardenne, ESCAPE EA7510, Laboratoire de Parasitologie-Mycologie, Pole de Biologie Pathologie, CHU de Reims, Reims, France.
Philippe PoirierUniversité Clermont Auvergne, Inserm, 3IHP, Centre Hospitalier Universitaire Clermont-Ferrand, Service de Parasitologie-Mycologie, Clermont-Ferrand, France.
Loic FavennecFrench National Cryptosporidiosis Reference Center, CHU de Rouen, Rouen, Normandie, France.
Julie BonhommeLaboratoire de Parasitologie-Mycologie, CHU de Caen, ToxEMAC-ABTE, Unicaen Université Normandie, Caen, France.
Alexandre AlanioInstitut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Mycology Translational Research Group, Mycology Department, Paris, France.
Fanny LanternierUniversité Paris Cité, Department of Infectious Diseases and Tropical Medicine, Necker - Enfants Malades University Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, 75014, France.
Marie Desnos-OllivierInstitut Pasteur, Université Paris Cité, National Reference Center for Invasive Mycoses and Antifungals, Mycology Translational Research Group, Mycology Department, Paris, France.
French Mycoses Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Intravenous injection drug use (IVDU) is an established but infrequent risk factor for yeast fungaemia. We aimed to identify features and outcomes of yeast fungaemia associated with IVDU in a nationwide surveillance network in France. Methods: We prospectively included episodes of yeast fungaemia in adults between 2012 and 2022. Episodes with any history of IVDU were considered IVDU-associated. We compared clinical characteristics, infecting species, antifungal treatments, and 90-day mortality between groups. We used Fisher's exact test for categorical variables and the Kruskal-Wallis test for continuous variables. Findings: We recorded 9549 episodes of yeast fungaemia among 9132 adults. Among these, 183 (1·9%) were IVDU-associated. Compared with non-IVDU, individuals with IVDU-associated fungaemia were younger and less likely to have a history of malignancy (13·8%, 20/145 Interpretation: IVDU-associated yeast fungaemia presents distinct clinical and microbiological characteristics, highlighting the need for tailored diagnosis and management. Funding: Financial support from Santé Publique France and Institut Pasteur, Paris.

Indexed as

CandidaInjection drug useYeast fungaemia

Identifiers

PMID40950950
PMCPMC12426822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.